SLC5A2 and diabetes mellitus: Evidence has shown that SGTL2 inhibitors such as dapagliflozin and empagliflozin improve outcomes in HF patients even in the absence of diabetes [33, 34], and recent guidelines recommend prescription of SGLT2 inhibitors in addition to standard HF therapies [35, 36].